Sorafenib: Experience and Better Management of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis | Zendy

JeanLuc Raoul | Zendy; Xavier Adhoute | Zendy; Guillaume Pénaranda | Zendy; H. Perrier | Zendy; Paul Castellani | Zendy; Valérie Oulès | Zendy; Marc Bourlière | Zendy

Open Access

Sorafenib: Experience and Better Management of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis

Author(s) -

JeanLuc Raoul,

Xavier Adhoute,

Guillaume Pénaranda,

H. Perrier,

Paul Castellani,

Valérie Oulès,

Marc Bourlière

Publication year - 2019

Publication title -

liver cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.916

H-Index - 34

eISSN - 2235-1795

pISSN - 1664-5553

DOI - 10.1159/000497161

Subject(s) - sorafenib , medicine , hepatocellular carcinoma , retrospective cohort study , univariate analysis , progressive disease , oncology , confidence interval , liver cancer , surgery , gastroenterology , multivariate analysis , disease

Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC). The management of its side effects is improving. This study aimed to assess, in real life, if this translates into a better prognosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research